Toggle navigation
Data Resources
Computing Analysis
Data Network
Standards
OpenLB
Open Library of Bioscience
Search
Advanced Search
Source: PubMed
Nature reviews. Drug discovery
Jan, 2015;14 (1): 3-4.
FDA reversal sends mixed message to multiple sclerosis community.
Elie Dolgin
Author Information
PMID: 25549578
DOI: 10.1038/nrd4526
Abstract
No abstract text available.
MeSH Term
Alemtuzumab
Antibodies, Monoclonal, Humanized
Clinical Trials as Topic
Drug Industry
Humans
Multiple Sclerosis
Residence Characteristics
United States
United States Food and Drug Administration
Chemicals
Antibodies, Monoclonal, Humanized
Alemtuzumab
News
Word Cloud
Created with Highcharts 10.0.0
FDA
reversal
sends
mixed
message
multiple
sclerosis
community
Similar Articles
Roanoke decision sends mixed message.
FDA pharmacogenomics guidance sends clear message to industry.
AHRQ sends mixed message on guidelines.
Sakharov sends message to vienna.
Congress sends a message.
Campaign sends wrong message.
Article sends wrong message.
Medicare ruling sends message to HCFA bureaucrats.
Cut to marijuana research sends strong message.
AONE sends message on shortage.
Cited By
No available data.
Posted by
5
X users
22
readers on Mendeley
See more details
